| Bioactivity | IDR 1002 is an IPO-38 antibody marker protein. IDR1002 catalyzes the conversion of arginine to citrulline. IDR 1002 can be usedto study the role of citrullinated modification of protein in cancer biology[1]. |
| Name | IDR 1002 |
| CAS | 1224095-25-3 |
| Sequence | Val-Gln-Arg-Trp-Leu-Ile-Val-Trp-Arg-Ile-Arg-Lys-NH2 |
| Shortening | VQRWLIVWRIRK-NH2 |
| Formula | C79H130N26O13 |
| Molar Mass | 1652.04 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Song S, et al. A Novel Citrullinated Modification of Histone 3 and Its Regulatory Mechanisms Related to IPO-38 Antibody-Labeled Protein. Front Oncol. 2019 Apr 18;9:304. |
IDR 1002
CAS: 1224095-25-3 F: C79H130N26O13 W: 1652.04
IDR 1002 is an IPO-38 antibody marker protein. IDR1002 catalyzes the conversion of arginine to citrulline. IDR 1002 can
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.